Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00128414
Status:
COMPLETED
Last Update Posted:
2011-02-16
First Post:
2005-08-08
Brief Title:
Study of Colchicine to Treat and Prevent Recurrent Pericarditis First Episode
Sponsor:
Azienda Sanitaria Locale 3 Torino
Organization:
Azienda Sanitaria Locale 3 Torino
Study Overview
Official Title:
Treatment and Prevention of Pericarditis With Colchicine A Multicenter Double Blind Randomized Trial The CORP Trial COlchicine for Recurrent Pericarditis
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CORP
Brief Summary:
The purpose of the study is to determine whether colchicine is safe and effective in the treatment and prevention of recurrent pericarditis first episode
Detailed Description:
Colchicine is safe and effective in the management of recurrent pericarditis after failure of conventional treatment Preliminary data have shown that it may be effective also in treatment of the first attack of recurrent pericarditis and the prevention of further recurrences
Comparisons The study will compare the safety and efficacy of colchicine in the treatment of the first attack of recurrent pericarditis and the secondary prevention of recurrences Colchicine will be used in addition to conventional treatment
Comparisons The study will compare the safety and efficacy of colchicine in the treatment of the first attack of recurrent pericarditis and the secondary prevention of recurrences Colchicine will be used in addition to conventional treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EUDRACT number 2005-001570-28 | None | None | None |